4.8 Article

MicroRNAome Genome: A Treasure for Cancer Diagnosis and Therapy

Journal

CA-A CANCER JOURNAL FOR CLINICIANS
Volume 64, Issue 5, Pages 311-336

Publisher

WILEY
DOI: 10.3322/caac.21244

Keywords

microRNA; diagnosis; therapy; cancer

Categories

Funding

  1. National Institutes of Health/National Cancer Institute [1UH2TR00943-01, 1 R01 CA182905-01]
  2. Developmental Research Award in prostate cancer, multiple myeloma, leukemia Specialized Programs of Research Excellence (SPORE) [P50 CA100632]
  3. Developmental Research Award in head and neck Specialized Programs of Research Excellence (SPORE) [P50 CA097007]
  4. Sister Institution Network Fund (SINF) University of Texas MD Anderson Cancer Center DKFZ grant in chronic lymphocytic leukemia (CLL)
  5. SINF
  6. Kidney Cancer Pilot Project
  7. University of Texas MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment
  8. Blanton-Davis Ovarian Cancer Sprint for Life Research Award
  9. Laura and John Arnold Foundation
  10. RGK Foundation
  11. Estate of C. G. Johnson, Jr
  12. CLL Global Research Foundation
  13. POSCCE [709/2010]

Ask authors/readers for more resources

The interplay between abnormalities in genes coding for proteins and noncoding microRNAs (miRNAs) has been among the most exciting yet unexpected discoveries in oncology over the last decade. The complexity of this network has redefined cancer research as miRNAs, produced from what was once considered genomic trash, have shown to be crucial for cancer initiation, progression, and dissemination. Naturally occurring miRNAs are very short transcripts that never produce a protein or amino acid chain, but act by regulating protein expression during cellular processes such as growth, development, and differentiation at the transcriptional, posttranscriptional, and/or translational level. In this review article, miRNAs are presented as ubiquitous players involved in all cancer hallmarks. The authors also describe the most used methods to detect their expression, which have revealed the identity of hundreds of miRNAs dysregulated in cancer cells or tumor microenvironment cells. Furthermore, the role of miRNAs as hormones and as reliable cancer biomarkers and predictors of treatment response is discussed. Along with this, the authors explore current strategies in designing miRNA-targeting therapeutics, as well as the associated challenges that research envisions to overcome. Finally, a new wave in molecular oncology translational research is introduced: the study of long noncoding RNAs. CA Cancer J Clin 2014; 64: 311-336. (C) 2014 American Cancer Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available